Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Inclusion Criteria Patients must have: EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests. For HIV+ patients: Patients must fail to meet the AIDS-defining criteria. CD4 lymphocyte count between 200 - 500 cells/mm3. Exclusion Criteria Co-existing Condition: Excluded: Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites. Concurrent Medication: Excluded: Patients who are likely to commence antiretrovirals within the 6-month study period. Patients using other immunomodulator therapies or other alternative therapies. Patients likely to require chemotherapy during the course of the study. Concurrent Treatment: Excluded: Patients who are likely to require significant UV light exposure during the study period. Patients who are likely to require radiation therapy during the course of the study. Prior Medication: Excluded: Prior exposure to DNCB. Patients who have used antiretroviral medications within the previous 3 months.